The Food and Drug Administration has approved 31 new drugs so far in 2017, with a handful of regulatory decisions scheduled for this month, according to Zacks Investment Research.
Here are six companies awaiting regulatory decisions this month, as listed by Zacks.
1. Mylan will learn if its biosimilar version of Roche's cancer drug Herceptin earns FDA approval this month.
2. Merck is seeking expanded approval for its drug Keytruda to treat a form of esophageal cancer. The drugmaker expects a response from the FDA Sept. 22.
3. Amgen and Allergan will learn if their biosimilar version of Roche's cancer drug Avastin earns FDA approval Sept. 14.
4. Bristol-Myers Squibb expects to hear from the FDA regarding an expanded approval for its drug Opdivo Sept. 24. The drugmaker is seeking approval to use the drug as a follow up treatment for patients with hepatocellular carcinoma.
5. Johnson & Johnson seeks FDA approval for its rheumatoid arthritis drug Plivensia. The drugmaker expects a response Sept. 23.
6. Neos Therapeutics will learn if the FDA approves its attention deficit hyperactive disorder drug Sept. 15.
More articles on supply chain:
McKesson donates $150k worth of medical supplies to Hurricane Harvey relief efforts
ROi acquires Healthcare Purchasing Alliance: 4 things to know
Hurricane Harvey spurs widespread fuel shortages ahead of Labor Day weekend